Oxford Biomedica PLC Results of TroVax® in Advanced Colorectal Cancer
24 February 2017 - 6:01PM
RNS Non-Regulatory
TIDMOXB
Oxford Biomedica PLC
24 February 2017
Oxford BioMedica Notes Encouraging Results of the Investigator
Led Phase I/II clinical trial of MVA-5T4 Immunotherapy (TroVax(R) )
and Low Dose Cyclophosphamide in Patients with Advanced Colorectal
Cancer
Both Cyclophosphamide and TroVax(R) independently shown to
induce highly beneficial anti-tumour immune responses, resulting in
significantly prolonged survival of advanced colorectal cancer
patients
Oxford, UK - 24 February 2017: Oxford BioMedica plc (LSE:OXB)
("Oxford BioMedica" or "the Group"), a leading gene and cell
therapy group, today notes the results from a Phase I/II clinical
trial of MVA-5T4 immunotherapy (TroVax(R) ) and low dose
cyclophosphamide (CPM) in patients with advanced colorectal cancer
(TaCTiCC). A poster was presented by the clinical investigators in
a poster session at the American Society of Clinical Oncology and
Society for Imumunotherapy of Cancer (ASCO-SITC) Clinical
Immuno-Oncology Symposium on 23 February 2017 in Orlando, USA.
The poster described the open-label Phase I/II clinical trial
involving 53 patients with inoperable, metastatic colorectal cancer
who were randomised to receive either no treatment, low dose CPM,
TroVax(R) only or low dose CPM followed by TroVax(R) . The primary
study endpoint was to assess increased anti-5T4 responses after
treatment on day 43 and the secondary endpoints were progression
free /overall survival and anti-5T4 responses over the trial
period.
The study findings demonstrated that significant anti-5T4 immune
responses were generated at treatment day 43. Secondary analysis
revealed that both CPM and TroVax(R) independently induced highly
beneficial anti-tumour immune responses, resulting in significant
survival of end stage colorectal cancer patients, without any major
toxicity. This was the first randomised study to show a benefit of
immunotherapy in advanced colorectal cancer patients.
Commenting on the results, John Dawson, Chief Executive Officer
of Oxford BioMedica, said: "The presentation by the Clinical
Investigators of the Phase I/II TaCTiCC study at the ASCO-SITC
Clinical Immuno-Oncology symposium showed the potential benefit
that Oxford BioMedica's immunotherapy (TroVax(R) ) treatment could
give to patients with advanced colorectal cancer."
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Tim Watts, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Chris Welsh/Laura Thornton
Jefferies (Corporate Broker): Tel: +44 (0)20 7029 8000
Gil Bar-Nahum
Simon Hardy
Lee Morton
Max Jones
Nicholas Moore
Notes to editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and
ex-vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
250 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGUPAPUPMGMW
(END) Dow Jones Newswires
February 24, 2017 02:01 ET (07:01 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024